clothes you wear?" exhibited DIF by gender in both psoriasis and AD samples, indicating that women were significantly more likely than men (at the same level of QoL) to affirm the item. Finally, the extensive DIF by disease observed indicates that it is not valid to compare the scores of AD and psoriasis patients using this measure. 4 AVENE Dermatological Laboratories, Brussels, Belgium OBJECTIVES: To assess the consequences of dermatological diseases on the quality of life of the patients. METHODS: Every Belgian Dermatologist received a sample of 30 questionnaires including the DLQI and the SF-12 that they distributed during the "National Week of Dermatology" to the first 30 patients coming to the consulting room. The SF-12 is a generic measure of health status, composed of two dimensions, a Physical one (PCS-12) and a Mental one (MCS-12). The lower the score, the more the quality of life is affected. The DLQI is a questionnaire designed to measure and compare disability in different skin conditions. The higher the score, the more the quality of life is affected. RESULTS: The male/female ratio was 37%/63% and the mean age was 46.76 years. Concerning the patients 'state of health, MCS-12 and PCS-12 were respectively 43.8 (SD = 11.3) and 48.1 (SD = 9.4); with a significant difference in the mental dimension between Flemish (46.4, SD = 10.6) and Walloons (40.7, SD = 11.3) (p = 0.0001). The quality of life score, assessed by the DLQI, shows a quality of life's impairment with a score of 6.1 (SD = 5.9). CONCLUSIONS: Our population reflect a QoL impairment comparable to the ranges obtained when initially validating the DLQI; i.e. for patients suffering psoriasis the DLQI mean score was 8.9, it was 4.3 for patients suffering from acne, and 6.7 for patients with viral warts. Concerning patients' health status we observe for every patient, whatever his skin disease was, an important impairment in the mental dimension of the SF-12 compared to a standard population and a slight one for the physical dimension (except for patients with acne who are younger, mean age = 28 years old).
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INTERPRETATION OF SCORES ON THE PSORIASIS INDEX OF QOL (PSORIQOL)
McKenna SP 1 , Meads DM 1 , Backhouse ME 2 1 Galen Research, Manchester, UK; 2 Novartis Pharma AG, Basel, Switzerland OBJECTIVES: The Psoriasis Index of Quality of Life (PSORIQoL) is a 25-item quality of life (QoL) scale specific to psoriasis. It has been shown to have excellent scaling properties and to be reproducible and valid. The aim of the present study was to assess the responsiveness of the PSORIQoL and provide data that will aid in the interpretation of scores on the measure. METHODS: Data from a 13-week, placebo-controlled clinical trial in psoriasis were analysed. PSORIQoL responsiveness was assessed using Effect Size (ES), Standardised Response Mean (SRM) and the Responsiveness Statistic (RS). The Standard Error of Measurement (SEM), a distribution-based method of interpreting scores was also calculated. An anchor-based Minimal Important Difference (MID; which provides an assessment of clinical meaningfulness) was derived by measuring QoL change accompanying changes in disease severity on a six-point Investigator's Global Assessment (IGA). The IGA ranges from zero (clear) to five (very severe disease). RESULTS: A total of 69 psoriasis patients completed the PSORIQoL (51/ 74% male; mean age 43.8 +/-11.7; baseline mean PSORIQoL = 12.2 +/-6.4; 13-week PSORIQoL = 9.8 +/-7.1). Effect Sizes ranged from 0.37 for the placebo arm to 0.67 for the most potent treatment arm. Changes for the whole sample were significant over time (p = .007), with SRM = 0.40 and RS = 0.51. According to ES, changes of 1.3, 3.2, and 5.1 represent small, moderate and large changes in PSORIQoL scores respectively. One SEM = 1.91; 1.96 SEM = 3.75. A move from Severe to Moderate and from Moderate to Mild disease on the IGA requires a change of 1.8 and 2.7 points, respectively in PSORIQoL scores. CONCLUSIONS: The PSORIQoL was shown to be responsive to treatment effects. The MID for the measure is between two and three points. 3 Avene Dermatological Laboratories, Lavaur, France OBJECTIVES: To evaluate the prevalence of "sensitive skin" among a representative sample of the French population.
METHODS:
We questioned a representative sample of the entire French population aged 15 years and above. The SF-12 is a generic measure of health status. The SF-12 is composed of two dimensions, a Physical Component Summary (PCS-12) and a Mental Component Summary (MCS-12). The results are standardised on the general US population [mean score of 50 (SD = 10)], so results can be meaningfully compared to an average and compared one another. The lower the score, the more the quality of life is affected. The SF-12 was intended for parents in order to assess their own quality of life. RESULTS: Out of the French population aged over 15 years, 51.9% felt that they had sensitive or very sensitive skin. An evaluation of the quality of life, using SF-12, revealed a change in the mental dimension of the score for subjects of both sexes, "very sensitive or sensitive" compared with "slightly or not sensitive": Men: 45.61 versus 49.70 (p < 0.0001), Women: 44.68 versus 47.30 (p = 0.0024). In addition, comparisons of the various degrees of sensitivity revealed significant differences for both men (very sensitive: 43.57, sensitive: 46.12, slightly: 48.43, not sensitive: 51.34) and women (very sensitive: 42.21, sensitive: 45.54, slightly: 46.99, not sensitive: 47.84) , showing that the alteration in the mental dimension was more severe when the skin was more sensitive. CONCLUSIONS: As measured by SF-12, the mental dimension of their quality of life was affected. The ICARE programme's objective is to asses patients' knowledge of the consequences of sun exposure. Its specificity and relevance are based on the fact that patients will be asked to fill in the questionnaire after a sunburn. METHODS: Every patient coming to an outpatient pharmacy in order to obtain an advice or treatment following a sunburn was remitted a questionnaire assessing the consequences of sun exposure. The Dermatology Life Quality Index (DLQI) is a validated questionnaire to measure and compare disability in different skin conditions. RESULTS: First results showed evidence of a QoL
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